CanSinoBIO Reports Outstanding H1 2024 Performance, Business News

HONG KONG, Aug 29, 2024 – (ACN Newswire) – CanSino Biologics Inc. (CanSinoBIO) today disclosed its performance report for the first half of 2024, with revenue reaching 303 million yuan, while losses were substantially reduced. The meningococcal conjugate vaccines demonstrated robust growth, particularly the Group ACYW135 Meningococcal Conjugate Vaccine (CRM197), known as MCV4 or Menhycia®. As…

Source link

About mysme

Check Also

CELEBRATING SONGKET IN THE UNITED STATES, Business Wires News

WASHINGTON, Oct. 1, 2024 /PRNewswire/ — Songket, Malaysia’s prized traditional textile, will take center stage …

Leave a Reply

Your email address will not be published. Required fields are marked *